David Hallal, Scholar Rock CEO, joins 'Fast Money' to talk its recent drug study results that found its drug taken in ...

Scholar Rock is also advancing its "pipeline in a product" strategy by exploring additional indications for apitegromab while leveraging its anti-myostatin platform with SRK-439.

Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a weight-loss drug trial.

Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 and Nasdaq Composite were up modestly. Scholar Rock, a biopharma company ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial ...

Scholar Rock, a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy and additional severe and debilitating ...

Scholar Rock's latest trial returned very positive results. The drug helps combat muscle loss in patients being treated with weight-loss drugs. Scholar Rock, a biopharma company, reported positive ...

While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the company may look for a partner in obesity while focusing on rare diseases.

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss ...

Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 and Nasdaq Composite were up modestly.